Form 4: Altimmune CBO Buys Shares via ESPP

Altimmune's Chief Business Officer, Raymond M. Jordt, acquired 4,571 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• Raymond M. Jordt, Chief Business Officer of Altimmune, Inc. (ALT), purchased 4,571 shares of the company's common stock.
• The transaction occurred on January 31, 2026, as part of the Issuer's 2019 Employee Stock Purchase Plan (ESPP).
• The shares were acquired at a price of $3.07 per share.
• This purchase pertains to the ESPP period from August 1, 2025, through January 31, 2026.
• The purchase price of $3.07 was based on 85% of the closing price of Altimmune's common stock on August 1, 2025.
• Following this transaction, Raymond M. Jordt beneficially owns 70,107 shares of Altimmune common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. While an ESPP purchase is routine, it demonstrates continued insider confidence and alignment with shareholder interests, without indicating any immediate negative developments.

Positives

• The acquisition of shares by a Chief Business Officer, even through an ESPP, can signal management's confidence in the company's future prospects.
• Participation in an Employee Stock Purchase Plan aligns the interests of management with those of shareholders.

Industry Context

StockSavvy.ai notes that routine insider purchases through an Employee Stock Purchase Plan are common and generally viewed as a minor positive, indicating continued alignment of management's financial interests with the company's performance. While not as strong a signal as open market purchases, it still reflects a belief in the company's value proposition.

Stakeholder Impact

• Shareholders may view this as a positive sign of management's continued belief in the company's value, potentially fostering confidence.

Key Dates

Keywords

Altimmune, ALT, Insider Trading, Form 4, ESPP, Stock Purchase, Raymond M. Jordt, Chief Business Officer